Regenxbio RGNX Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $87.82M-48.5% | $170.44M+5.7% | $161.32M+3.6% | $155.78M-0.6% | $156.72M+88.1% | ||
| $232.55M+1.9% | $228.3M+4.2% | $219.07M+0.8% | $217.4M+5.1% | $206.77M-0.8% | ||
| $83.82M+1.2% | $82.86M+2.9% | $80.53M+1.0% | $79.7M+1.3% | $78.68M+2.7% | ||
| $344.51M+3.9% | $331.64M+4.9% | $316.25M-1.3% | $320.38M+2.0% | $314.07M-0.8% | ||
| -$256.69M-59.2% | -$161.2M-4.0% | -$154.93M+5.9% | -$164.6M-4.6% | -$157.36M+32.6% | ||
| -292.3%-198pp | -94.6%+1.5pp | -96%+9.6pp | -105.7%-5.3pp | -100.4%+180pp | ||
| $45.15M+0.3% | $45.01M+6.8% | $42.15M+41.4% | $29.8M+54.8% | $19.26M+52.1% | ||
| $11.75M-4.1% | $12.25M-35.6% | $19.02M+1.8% | $18.67M-0.5% | $18.76M+0.2% | ||
| -$33.33M-2.0% | -$32.68M-42.2% | -$22.99M-109% | -$10.97M-3,195% | -$333K-105% | ||
| -$290.01M-49.6% | -$193.88M-9.0% | -$177.92M-1.3% | -$175.57M-11.3% | -$157.69M+30.6% | ||
| -330.2%-216pp | -113.8%-3.5pp | -110.3%+2.4pp | -112.7%-12.1pp | -100.6%+172pp | ||
| -$5.60-48.9% | -$3.76-8.7% | -$3.46-0.9% | -$3.43-10.6% | -$3.10+32.6% | ||
| -$5.60-48.9% | -$3.76-8.7% | -$3.46-0.9% | -$3.43-10.6% | -$3.10+32.6% | ||
| 207.2M+0.5% | 206.2M+1.0% | 204.1M+0.4% | 203.2M+0.4% | 202.3M+2.9% | ||
| 207.2M+0.5% | 206.1M+1.0% | 204M+0.4% | 203.2M+0.4% | 202.3M+2.9% | ||
| $27.94M+37.6% | $20.3M-1.9% | $20.69M-24.4% | $27.35M-16.4% | $32.72M-2.5% | ||
| -$200K-11.7% | -$179K+81.3% | -$958K-3.0% | -$930K-1.8% | -$914K-5.7% | ||
| $74K-10.8% | $83K-43.9% | $148K-3.9% | $154K-4.9% | $162K-6.9% | ||
| -$290.12M-49.7% | -$193.82M-8.9% | -$177.99M-2.3% | -$174.06M-12.1% | -$155.22M+30.5% | ||
| $11.75M-4.1% | $12.25M-35.6% | $19.02M+1.8% | $18.67M-0.5% | $18.76M+0.2% | ||
| —— | —— | $89K-94.7% | $1.68M-36.2% | $2.63M-31.7% | ||
| —— | —— | $89K-94.7% | $1.68M-36.2% | $2.63M-31.7% | ||
| —— | —— | —— | —— | —— | ||
| $87.82M-48.5% | $170.44M+5.7% | $161.32M+3.6% | $155.78M-0.6% | $156.72M+88.1% | ||
| -$256.69M-59.2% | -$161.2M-4.0% | -$154.93M+5.9% | -$164.6M-4.6% | -$157.36M+32.6% | ||
| -$241.17M-65.7% | -$145.58M-4.6% | -$139.16M+6.4% | -$148.75M-5.2% | -$141.37M+34.9% | ||
| -$241.17M-65.7% | -$145.58M-4.6% | -$139.16M+6.4% | -$148.75M-5.2% | -$141.37M+34.9% | ||
| -274.6%-189pp | -85.4%+0.8pp | -86.3%+9.2pp | -95.5%-5.3pp | -90.2%+170pp | ||
| -$256.69M-59.2% | -$161.2M-4.0% | -$154.93M+5.9% | -$164.6M-4.6% | -$157.36M+32.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Regenxbio's revenue?
- Regenxbio (RGNX) generated $87.8M in revenue over the trailing twelve months, down 44.0% year over year.
- Is Regenxbio profitable?
- Regenxbio is not currently profitable: it reported a net loss of $290.0M over the trailing twelve months, a -330.2% net margin.
- What are Regenxbio's profit margins?
- Gross margin is 59.7% and operating margin is -292.3%, with a -330.2% net margin.
- What is Regenxbio's earnings per share?
- Regenxbio's diluted EPS over the trailing twelve months is $-5.60.
- Where does Regenxbio's income statement data come from?
- Every line is extracted from Regenxbio's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
